GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background: After liver injury, the repair process comprises activation and proliferation of hepatic stellate cells (HSCs), which produce extracellular matrix (ECM) proteins. Peroxisome proliferator-activated receptor beta/delta ( PPARβ/δ) is highly expressed in these cells, but its function in liver repair remains incompletely understood. This study investigated whether activation of PPARβ/δ with the ligand GW501516 influenced the fibrotic response to injury from chronic carbon tetrachloride (CCl 4 ) treatment in mice. Wild type and PPARβ/δ-null mice were treated with CCl 4 alone or CCl 4 co-administered with GW501516. To unveil mechanisms underlying the PPARβ/δ-dependent effects, we analyzed the proliferative response of human LX-2 HSCs to GW501516 in the presence or absence of PPARβ/δ. Results: We found that GW501516 treatment enhanced the fibrotic response. Compared to the other experimental groups, CCl 4 /GW501516-treated wild type mice exhibited increased expression of various profibrotic and pro-inflammatory genes, such as those involved in extracellular matrix deposition and macrophage recruitment. Importantly, compared to healthy liver, hepatic fibrotic tissues from alcoholic patients showed increased expression of several PPAR target genes, including phosphoinositide-dependent kinase-1, transforming growth factor beta-1, and monocyte chemoattractant protein-1. GW501516 stimulated HSC proliferation that caused enhanced fibrotic and inflammatory responses, by increasing the phosphorylation of p38 and c-Jun N-terminal kinases through the phosphoinositide-3 kinase/protein kinase-C alpha/beta mixed lineage kinase-3 pathway. Conclusions: This study clarified the mechanism underlying GW501516-dependent promotion of hepatic repair by stimulating proliferation of HSCs via the p38 and JNK MAPK pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 PPARβ/δ controls pathways that regulate proliferation of LX-2 cells. Stable PPARβ/δ knockdown (KD) was performed by lentiviral transduction of LX-2 cells with a siRNA against PPARβ/δ. Control LX-2 cells were transduced with the control vector. A) qRT-PCR showed reduced PPARβ/δ expression in PPARβ/δ KD LX-2 cells. The control values were set to 1. Results are means ± SD of at least three independent experiments performed in triplicate. B-F) Control and PPARβ/δ KD LX-2 cells were starved for 24 h in serum-free media and then treated for 48 h with DMSO (control) or (B) 100 nM GW501516, or (C-F) 100 nM GW501516 in the presence or absence of 10 nM or 100 nM of (C) PD98059, (D) LY294002, (E) JNK inhibitor II, or (F) SB202190. All inhibitors were added 30 min before GW501516 treatment. Cell proliferation was determined by [3H]-thymidine incorporation. Values are expressed as a percentage of the values from DMSO-treated LX-2 cells, which were set to 100%. Values represent means ± SEM from at least five independent experiments performed in triplicate; * = p<0.05 compared to DMSO-treated cells.](https://figures.cochat.ai/paper-figures/da233f4835d94f63b5b935efbb2537f7/gw501516-activated-ppar-promotes-liver-fibrosis-via-p38-jnk-mapk-induced-hepatic-figure-6.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the PPAR-δ ligand GW501516 was linked to enhanced fibrotic and inflammatory responses due to an increased phosphorylation of p38 and c-Jun-N-terminal kinases.[149].”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295 · cited 1×
“Those studies showed that multiple stress stimuli increased the activity of SAPK/JNK and p38 MAPKs, which in turn activated several transcription factors implicated in cell proliferation and differentiation [26].”
BackgroundPeroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086 · cited 2×
“Distinct genes produce three PPAR isotypes, PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3) [5].”
BackgroundSelf-citationMolecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury
Friedman, S. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2247 · Cited by 2,080 · cited 3×
“This study focused on the role of GW501516-activated PPARβ/δ in mouse liver fibrosis after long-term CCl4 treatment, which is more relevant to liver diseases in human [2,3].”
BackgroundHepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model
Weber, L. W. D., Boll, M., & Stampfl, A. (2003) · Critical Reviews in Toxicology · doi:10.1080/713611034 · Cited by 1,777
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Desvergne, B. (1999) · Endocrine Reviews · doi:10.1210/er.20.5.649 · Cited by 1,251
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis
Xu, L., Hui, A. Y., Albanis, E., Arthur, M. J., O’Byrne, S. M., Blaner, W. S., Mukherjee, P., Friedman, S. L., & Eng, F. J. (2005) · Gut · doi:10.1136/gut.2004.042127 · Cited by 1,014 · cited 2×
“These cells express key genes involved in hepatic fibrosis [17].”
BackgroundWiznerowicz, M., & Trono, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8957-8951.2003 · Cited by 701 · cited 1×
“In addition, an internal cassette allowed expression of the green fluorescent protein (GFP) marker gene under the control of the elongation factor (EF-1) α promoter [43].”
BackgroundMixed-lineage kinase control of JNK and p38 MAPK pathways
Gallo, K. A., & Johnson, G. L. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm906 · Cited by 572 · cited 2×
“It was previously established that MLK3 phosphorylates and activates the MAP2K isoforms MKK4/7 and MKK3/6, which then activate JNK and p38, respectively [19,20,34,35].”
BackgroundGalli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440 · cited 1×
“PPARγ, activated by glitazones, down-regulates inflammation, collagen synthesis, HSC activation and proliferation [7,8].”
BackgroundThe role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis
Elsharkawy, A. M., Oakley, F., & Mann, D. A. (2005) · Apoptosis · doi:10.1007/s10495-005-1055-4 · Cited by 419 · cited 3×
“Currently, the only effective treatment for end-stage cirrhosis is liver transplantation [1].”
BackgroundMichalik, L., Desvergne, B., Tan, N. S., Basu-Modak, S., Escher, P., Rieusset, J., Peters, J. M., Kaya, G., Gonzalez, F. J., Zakany, J., et al. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200011148 · Cited by 406 · cited 2×
“CCl4 treatment of mice Wild type and PPARβ/δ-null [23] 6–8 week-old male mice of a mixed genetic background Sv129/C57BL/6, were maintained at 23 °C on a 12-h light–dark cycle with free access to water and a standard diet.”
BackgroundMethodSelf-citationTournier, C., Dong, C., Turner, T. K., Jones, S. N., Flavell, R. A., & Davis, R. J. (2001) · Genes & Development · doi:10.1101/gad.888501 · Cited by 359 · cited 1×
“It was previously established that MLK3 phosphorylates and activates the MAP2K isoforms MKK4/7 and MKK3/6, which then activate JNK and p38, respectively [19,20,34,35].”
BackgroundDi-Poı̈, N., Tan, N. S., Michalik, L., Wahli, W., & Desvergne, B. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00646-9 · Cited by 327 · cited 1×
“Consistent with this finding, ligand-activated PPARβ/δ in skin increased keratinocyte survival upon exposure to stress through PI3K signaling; this was reflected by increased Akt1 activity [27].”
BackgroundSelf-citationMolecular mechanisms of hepatic fibrogenesis
Parsons, C. J., Takashima, M., & Rippe, R. A. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04659.x · Cited by 310 · cited 1×
“In fact, it was previously shown that MAPKs p38 and JNK were positive regulators of HSC proliferation [1,24,25].”
BackgroundInvolvement of PPAR nuclear receptors in tissue injury and wound repair
Michalik, L. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27958 · Cited by 239 · cited 1×
“Peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors of the nuclear hormone receptor family, which have been associated with liver fibrosis [4].”
BackgroundHASHIMOTO, S., GON, Y., TAKESHITA, I., MATSUMOTO, K., MARUOKA, S., & HORIE, T. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.1.2005069 · Cited by 228 · cited 1×
“Furthermore, CEP-1347, the small-molecule inhibitor of all MLK members, caused reductions in pulmonary fibrosis [37], pancreatitis [38], and neurodegeneration [39] by inhibiting JNK activation.”
BackgroundTaimr, P., Higuchi, H., Kocova, E., Rippe, R. A., Friedman, S., & Gores, G. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50002 · Cited by 227 · cited 1×
“These cells are in a pre-activated state and they progressively express activation markers after cultivation [18].”
BackgroundGressner, A. M. (1998) · Cell and Tissue Research · doi:10.1007/s004410051073 · Cited by 199 · cited 3×
“This study focused on the role of GW501516-activated PPARβ/δ in mouse liver fibrosis after long-term CCl4 treatment, which is more relevant to liver diseases in human [2,3].”
BackgroundNadra, K., Anghel, S. I., Joye, E., Tan, N. S., Basu-Modak, S., Trono, D., Wahli, W., & Desvergne, B. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.3266-3281.2006 · Cited by 198 · cited 1×
“The short interfering RNA (siRNA) was cloned into a pLV-TH lentivirus vector under the control of the polymerase III-dependent H1 promoter [42].”
MethodSelf-citationMLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation
Chadee, D. N., & Kyriakis, J. M. (2004) · Nature Cell Biology · doi:10.1038/ncb1152 · Cited by 163 · cited 6×
“The MAPK extracellular signalregulated kinase 1/2 (Erk1/2) pathway inhibitor, PD98049 (MEK1 inhibitor), had no effect on GW501516-inducible LX-2 cell proliferation (Figure 6C).”
BackgroundInfluentialProtection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202464109 · Cited by 157 · cited 4×
“In line with our results, a recent study also demonstrated a profibrotic effect of the PPARβ/δ ligand GW501516 after short-term CCl4 administration in mice [15].”
BackgroundResultInfluentialMetabolic Stress Signaling Mediated by Mixed-Lineage Kinases
Jaeschke, A., & Davis, R. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.07.008 · Cited by 150 · cited 5×
“The MAPK extracellular signalregulated kinase 1/2 (Erk1/2) pathway inhibitor, PD98049 (MEK1 inhibitor), had no effect on GW501516-inducible LX-2 cell proliferation (Figure 6C).”
BackgroundInfluentialHellemans, K., Michalik, L., Dittie, A., Knorr, A., Rombouts, K., de Jong, J., Heirman, C., Quartier, E., Schuit, F., Wahli, W., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50015 · Cited by 137 · cited 4×
“In rats, acute treatment with L165041 and CCl4 increased the expression of fibrotic markers [10].”
BackgroundResultSelf-citationTAK1/JNK and p38 have opposite effects on rat hepatic stellate cells
Schnabl, B., Bradham, C. A., Bennett, B. L., Manning, A. M., Stefanovic, B., & Brenner, D. A. (2001) · Hepatology · doi:10.1053/jhep.2001.28790 · Cited by 129 · cited 1×
“In fact, it was previously shown that MAPKs p38 and JNK were positive regulators of HSC proliferation [1,24,25].”
BackgroundSugimoto, R., Enjoji, M., Kohjima, M., Tsuruta, S., Fukushima, M., Iwao, M., Sonta, T., Kotoh, K., Inoguchi, T., & Nakamuta, M. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01130.x · Cited by 115 · cited 1×
“It was previously demonstrated that acetaldehyde induced PKC activation, which then increased HSC proliferation and activation [28-31] and collagen production [32,33].”
BackgroundZach‐Avec, D., Brolinson, A., Fisher, R. M., Carneheim, C., Csikasz, R. I., Bertrand‐Michel, J., Borén, J., Guillou, H., Rudling, M., & Jacobsson, A. (2010) · The FASEB Journal · doi:10.1096/fj.09-152298 · Cited by 112
Self-citationSaporito, M. S., Hudkins, R. L., & Maroney, A. C. (2002) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70081-x · Cited by 108 · cited 1×
“Furthermore, CEP-1347, the small-molecule inhibitor of all MLK members, caused reductions in pulmonary fibrosis [37], pancreatitis [38], and neurodegeneration [39] by inhibiting JNK activation.”
BackgroundChadee, D. N., Xu, D., Hung, G., Andalibi, A., LIM, D. J., Luo, Z., Gutmann, D. H., & Kyriakis, J. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510651103 · Cited by 97 · cited 1×
“These cells also exhibited destabilized B-Raf/Raf1 complexes [36].”
BackgroundShan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., & Peters, J. M. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn142 · Cited by 97 · cited 2×
“In contrast, other studies concluded that GW0742- or KD3010-activated PPARβ/ δ attenuated CCl4-induced hepatotoxicity [13,15].”
BackgroundResultPang, M., de la Monte, S. M., Longato, L., Tong, M., He, J., Chaudhry, R., Duan, K. I., Ouh, J., & Wands, J. R. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.021 · Cited by 93 · cited 1×
“In a model of chronic ethanol-fed rats, L165041 reduced hepatic injury, oxidative stress and DNA damage, and improved the regenerative response in livers [14].”
BackgroundShan, W., Nicol, C. J., Ito, S., Bility, M. T., Kennett, M. J., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2008) · Hepatology · doi:10.1002/hep.21925 · Cited by 93 · cited 1×
“In contrast, PPARβ/δ was protective against azoxymethane and CCl4-induced hepatotoxicity and, when activated with the synthetic ligand GW0742, down-regulated proinflammatory gene expression in CCl4-treated mice [12,13].”
BackgroundKim, K.-Y., Kim, B.-C., Xu, Z., & Kim, S.-J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313947200 · Cited by 91 · cited 2×
“It was previously established that MLK3 phosphorylates and activates the MAP2K isoforms MKK4/7 and MKK3/6, which then activate JNK and p38, respectively [19,20,34,35].”
BackgroundHellemans, K., Rombouts, K., Quartier, E., Dittié, A. S., Knorr, A., Michalik, L., Rogiers, V., Schuit, F., Wahli, W., & Geerts, A. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200376-jlr200 · Cited by 64 · cited 1×
“Furthermore, PPARβ/δ transcriptional activation by the selective synthetic ligand L165041 enhanced proliferation of both quiescent and activated HSCs [10] and PPARβ/δ modulated the expression of vitamin A metabolism-related genes in HSCs undergoing activation [11].”
BackgroundSelf-citation(1994) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a045537 · Cited by 63 · cited 1×
“It was previously demonstrated that acetaldehyde induced PKC activation, which then increased HSC proliferation and activation [28-31] and collagen production [32,33].”
BackgroundEffects of PPARg agonist pioglitazone on rat hepatic fibrosis
Yuan, G., Zhang, M., & Gong, Z. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i7.1047 · Cited by 53 · cited 1×
“PPARγ, activated by glitazones, down-regulates inflammation, collagen synthesis, HSC activation and proliferation [7,8].”
BackgroundWagner, A. C. C., Mazzucchelli, L., Miller, M., Camoratto, A. M., & Göke, B. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g165 · Cited by 51
Takahashi, M. (2003) · Hepatology Research · doi:10.1016/s1386-6346(03)00112-8 · Cited by 46
Manautou, J. E., Silva, V. M., Hennig, G. E., & Whiteley, H. E. (1998) · Toxicology · doi:10.1016/s0300-483x(98)00013-4 · Cited by 43 · cited 1×
“The synthetic PPARα ligand, clofibrate, protects against CCl4-induced liver fibrosis [6].”
BackgroundA Novel Role for Mixed Lineage Kinase 3 (MLK3) in B-Raf Activation and Cell proliferation
Chadee, D. N., & Kyriakis, J. M. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1187 · Cited by 36 · cited 2×
“MLK3 stimulates the MAPKKs MKK3/6 and MKK4, which finally activate p38 and JNK MAPKs in the last steps of initiating HSC proliferation [19-22].”
BackgroundAnania, F. A., Womack, L., Potter, J. J., & Mezey, E. (1999) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04111.x · Cited by 34 · cited 1×
“It was previously demonstrated that acetaldehyde induced PKC activation, which then increased HSC proliferation and activation [28-31] and collagen production [32,33].”
BackgroundKnight, B., Yeap, B. B., Yeoh, G. C., & Olynyk, J. K. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi138 · Cited by 31 · cited 1×
“Previous studies have shown that the PPARγ agonist ciglitazone diminished adult liver progenitor (oval) cell response and decreased fibrosis in mice fed with a choline deficient, methionine supplemented diet, while the PPARβ/δ ligand GW501516 did not affect oval cell proliferation or liver fibrosis in the same model […”
BackgroundSario, A. D., Bendia, E., Svegliati‐Baroni, G., Marzioni, M., Ridolfi, F., Trozzi, L., Ugili, L., Saccomanno, S., Jézéquel, A. M., & Benedetti, A. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00242-2 · Cited by 24 · cited 1×
“It was previously demonstrated that acetaldehyde induced PKC activation, which then increased HSC proliferation and activation [28-31] and collagen production [32,33].”
BackgroundHepatic Stellate Cells and Liver Retinoid Content in Alcoholic Liver Disease in Humans
Hautekeete, M. L., Dodeman, I., Azais-Braesco, V., Van den Berg, K., Seynaeve, C., & Geerts, A. (1998) · Alcoholism: Clinical & Experimental Research · doi:10.1097/00000374-199804000-00028 · Cited by 18 · cited 1×
“Liver biopsies were collected by transparietal puncture from 8 healthy individuals and 12 patients (10 males, 2 females; aged 48–69 years) with alcohol-caused liver fibrosis or cirrhosis, diagnosed on clinical, biological, and histological grounds [41].”
MethodEffect of Protein Kinase C Activation and Inhibition on Rat Hepatic Stellate Cell Activation
Ramm, G. A., Li, L., Britton, R. S., O’Neill, R., & Bacon, B. R. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1022857313917 · Cited by 13 · cited 1×
“It was previously demonstrated that acetaldehyde induced PKC activation, which then increased HSC proliferation and activation [28-31] and collagen production [32,33].”
Background
Cited by
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Metabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 279
Metadata
- Authors
- Kostadinova, R., Montagner, A., Gouranton, E., Fleury, S., Guillou, H., Dombrowicz, D., Desreumaux, P., & Wahli, W.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Toxicologie Alimentaire (FR)
- University of Lausanne (CH)
- Inserm (FR)
- Corresponding author
- Wahli, Walter
- ORCID
- Venue
- Cell & Bioscience
- Published
- 2012-10
- Volume
- 2
- Issue
- 1
- Pages
- 34-34
- ISSN
- 2045-3701 (ISSN-L)
- PMC
- PMC3519722
- OpenAlex
- W2120100784
- Cited by
- 83
- References
- 43
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 10 · 2023: 5 · 2022: 6 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 6 · 2014: 6 · 2013: 7
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Cell & Bioscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- IRIS (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion, other-oa)
- Funders
- National Science Foundation
- Institut National de la Santé et de la Recherche Médicale
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Fondation pour la Recherche Médicale
- Université de Lausanne
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- PPARδ, GW501516, liver fibrosis, p38 MAPK, JNK MAPK, phosphatidylinositol 3-kinase/Akt signaling, extracellular matrix deposition, liver inflammation, macrophage recruitment, PPAR target genes, alcoholic liver disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.